ABCs Report: Methicillin-Resistant Staphylococcus aureus, 2013

May 18, 2015: Content on this page kept for historical reasons.

Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Network

Print-friendly version of this surveillance report Cdc-pdf[3 pages]

ABCs Areas

California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia (8 county Atlanta area); Maryland (Baltimore City and County); Minnesota (2 metro Twin City counties); New York (1 Rochester county); Oregon (3 county Portland area); Tennessee (1 Nashville county).

ABCs Population

The surveillance areas represent 19,842,441 persons
Source: National Center for Health Statistics bridged race vintage 2013 postcensal file.

ABCs Case Definition

Invasive methicillin-resistant Staphylococcus aureus (MRSA) disease: isolation of MRSA from a normally sterile site in a resident of the surveillance area in 2013. Cases of disease are classified into one of three epidemiologic classifications. A case is classified as hospital-onset (HO) if the MRSA culture was obtained on or after the fourth calendar day of hospitalization, where admission is hospital day 1; as healthcare-associated community-onset (HACO) if the culture was obtained in an outpatient setting or before the fourth calendar day of hospitalization and had one or more of the following: 1) a history of hospitalization, surgery, dialysis, or residence in a long term care facility in the previous year, or 2) the presence of a central vascular catheter (CVC) within 2 days prior to MRSA culture; and as community-associated (CA) if none of the previously mentioned criteria are met.

ABCs Methodology

ABCs personnel routinely contacted all microbiology laboratories serving healthcare facilities in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Convenience samples of isolates were collected and sent to CDC for routine testing, including antimicrobial susceptibility testing, toxin testing, SCCmec typing, and spa typing. Pulsed field gel electrophoresis (PFGE) of all isolates was discontinued in 2008; up until 2012, PFGE was inferred based on a validated algorithm. Starting in 2012, spa typing was added to the routine laboratory testing. Pulsed field type is currently inferred based on spa type, inferred MLST clonal complex and molecular characteristics of the isolates. In 2013, isolates were only collected in five sites (California, Georgia, Minnesota, New York, and Tennessee). Regular laboratory audits were performed to ensure completeness of case detection.

Rates of invasive MRSA disease among all patients were calculated using population estimates for 2013. Cases with unknown race were assigned race based on distribution of known age, race, and gender by EIP site. Confidence intervals for nationally estimated incidence rates of disease and mortality were calculated based on the gamma distribution (Stat Med, 1997 16:791-801).

Rates of invasive MRSA disease among patients who were undergoing chronic dialysis treatment were calculated using the December 31, 2012 point prevalent counts of patients on dialysis from the United States Renal Data System (USRDS)External.

ABCs Results

Reported Race among 4576 Cases
Race No. (Ratea)
White 2843 (20.6)
Black 1563 (40.6)
Other 170 (7.9)

Unknown race (n=390) distributed amongst known

aCases per 100,000 population for ABCs areas (crude rates)

 

Reported Cases on Chronic Dialysis (n=872)
Dialysis and Access Type No. (%)
Peritoneal 29 (3.3)
Hemodialysis 834 (95.6)
Hemodialysis – AV Fistula/Graft 340 (39.0)
Hemodialysis – CVC 462 (53.0)
Hemodialysis – Unkown 32 (3.7)
Unkown 9 (1.0)

 

Cases, Deaths & Inferred PFGE type by Epidemiological Classification
MRSA Class No. (Rate)
Casesb
No. (Rate)
Deaths c
Inferred PFGE Type (%)
Tot N
Inferred PFGE Type (%)
USA100
Inferred PFGE Type (%
USA300
Inferred PFGE Type (%)
USA500/
Iberian
CA 998 (5.0) 102 (0.5) 150 22 (14.7) 103 (68.7) 6 (4.0)
HCAa 3529 (17.8) 480 (2.4) 554 243 (43.9) 165 (29.8) 75 (13.5)
HCA-HO 704 (3.6) 135 (0.7) 111 48 (43.2) 41 (36.9) 9 (8.1)
HCA-HACO 2825 (14.2) 345 (1.7) 443 195 (44.0) 124 (28.0) 66 (14.9)

aHCA: Healthcare-associated invasive MRSA infection; sum of patients that are classified as either the HO or HACO classes
bn= 49 epidemiologic category unknown
cn=6; epidemiologic category unknown
 

Reported Clinical Syndrome by Epidemiologic Class
Syndromea CA
(n=998)
No. (%)
HACO
(n=2825)
No. (%)
HO
(n=704)
No. (%)
Bloodstream Infection with other syndromeb 521 (52.2) 1363 (48.2) 216 (30.7)
Bloodstream Infection with no other syndromeb 210 (21.0) 963 (34.1) 247 (35.1)
Pneumonia 141 (14.1) 349 (12.4) 95 (13.5)
Pneumonia – Lower Respiratory Infectionc 44 (4.4) 103 (3.6) 28 (4.0)
Osteomyelitis 154 (15.4) 418 (14.8) 142 (20.2)
Endocarditis 75 (7.5) 168 (5.9) 29 (4.1)
Cellulitis 180 (18.0) 233 (8.2) 56 (8.0)
Wounds – Surgicald 8 (0.8) 136 (4.8) 28 (4.0)
Wounds – Decubitus/Pressure Ulcers 10 (1.0) 53 (1.9) 11 (1.6)
Wounds – Skin Abscessese 94 (9.4) 87 (3.1) 18 (2.6)
Wounds – Other woundsf 32 (3.2) 96 (3.4) 32 (4.5)
Wounds – Traumatic 11 (1.1) 6 (0.2) 3 (0.4)

aSome case patients had more than one syndrome.
bCatheter site infection or AV fistula infection only are included in BSI with other syndrome.
cLower Respiratory Infection is defined as: a patient with pneumonia documented in their discharge summary who has a positive MRSA non-sterile respiratory specimen with accompanying chest radiology results documenting any of the following: bronchopneumonia/pneumonia, air space density/opacity, new or changed infiltrates.
dCombines deep tissue/organ infection and infection of a surgical wound, post operatively.
eCategory includes skin abscess, necrotizing fasciitis, gangrene.
fCategory includes non-traumatic and other chronic wound infections.

This figure is a bar chart that depicts the incidence, per one hundred thousand persons, of invasive MSRA (methicillin-resistant Staphylococcus aureus) by epidemiological class and age group in 2012. The three epidemiological classes charted are; community-associated (CA), healthcare-associated community-onset (HACO), and hospital-onset (HO). The eight age groups charted are; less than 1 year, 1 year, 2-4 years, 5-17 years, 18-34 years, 35-49 years, 50-64 years, greater than or equal to 65 years.

 

National Estimates and Adjusted Incidence Rates of Invasive MRSA Infections
Epidemiologic Category Estimated Cases of Infection
Non-Dialysis Patients Dialysis Patients Total
Estimated No. Incidence Rate (Confidence Interval)a Estimated No. Incidence Rate (Confidence Interval)b Estimated No. Incidence Rate (Confidence Interval)d
CA 16,117 5.10 (3.92-6.74) NA NA 16,117 5.10 (3.92-6.74)
HCA 43,864 13.90 (12.02-16.23) 13,919 3079.89 (2331.21-4076.80) 57,783 18.28 (15.34-22.04)
HCA-HO 9,820 3.11 (2.24-4.39) 1,584 350.44 (153.54-710.62) 11,404 3.61 (2.46-5.40)
HCA-HACO 34,044 10.78 (9.21-12.76) 12,335 2729.00 (2026.78-3681.88) 46,379 14.67 (12.10-18.00)
Overallc 60,772 19.25 (16.94-22.05) 13,921 3079.89 (2331.21-4076.80) 74,693 23.63 (20.24-27.84)

aNational Estimates and Incidence (no. per 100,000 population per year) are adjusted for age, race, gender and receipt of chronic dialysis using 2013 US Census Data.
bNational Estimates and Incidence (no. per 100,000 dialysis patients per year) for dialysis patients are adjusted for age, race and gender using 2012 USRDS point prevalence data.
c49 cases could not be classified into an epidemiological category or category is unknown and therefore are counted in the overall estimate only.
dStarting in 2011, confidence intervals on national estimates were determined for each of the 72 age/race/gender/dialysis specific strata and summarized for an overall national estimate, accounting for variance across all strata producing a more conservative estimate (with wider confidence intervals) compared to estimates prior to 2011.

 

National Estimates and Adjusted Incidence Rates for Mortality among Cases
Epidemiologic Class Estimated No. Mortality Rate
(Confidence Interval)a
CA 1,710 0.54 (0.28-1.00)
HCA 8,150 2.58 (1.68-4.01)
HCA-HO 2,331 0.74 (0.33-1.59)
HCA-HACO 5,819 1.84 (1.12-3.02)
Overallb 9,937 3.14 (2.14-4.68)

aNational Estimates and Mortality Rate (no. per 100,000 population per year) are adjusted for age, race, gender and receipt of chronic dialysis using 2013 US Census Data
b49 cases could not be classified into an epidemiological category or category is unknown and therefore are counted in the overall estimate only.

 

National Metric for Healthy People 2020 and the Department of Health and Human Services Action Plan to Prevent Healthcare-Associated Infections
Disease Rate Estimate of Cases in United States.a
Baseline (07-08) 2013 % Change Baseline (07-08) 2013 Difference
HCA 27.08 18.28 -32.50 82,000 58,000 24,000

aDisease Rate (no. per 100,000 population per year) and National Estimates are adjusted for age, race, gender and receipt of chronic dialysis using 2012 US Census Data

ABCs Discussion

Surveillance data from 2013 represent the ninth full year of performing population-based surveillance for invasive MRSA infections through the Emerging Infections Program/Active Bacterial Core Surveillance Activity.

Compared to 2012, incidence of healthcare-associated MRSA decreased by 1.01% while incidence of community-associated MRSA increased by 6.51%. Compared to the baseline incidence (2007-2008 calendar years) identified in the HHS Action Plan, there was a decrease of 32.50% for healthcare-associated MRSA.

Citation

  1. Centers for Disease Control and Prevention. 2013. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2013.

Top of Page

View Page In:Cdc-pdf PDF [338K]
Page last reviewed: May 18, 2015 (archived document)